Le Lézard
Classified in: Health, Covid-19 virus
Subject: ACC

The Nomination Committee Proposes Unchanged Board Fees


STOCKHOLM, March 31, 2020 /PRNewswire/ -- As a consequence of the situation concerning the coronavirus pandemic, Essity's Nomination Committee has decided to withdraw its proposal that Essity's Annual General Meeting on April 2, 2020 approve an increase in Board fees (item 11 on the agenda). 

Instead, the Nomination Committee proposes unchanged Board fees compared with 2019. The Nomination Committee's all other proposals to the Annual General Meeting remain unchanged.

CONTACT:

For further information, please contact:
Helena Stjernholm, Chairman of Nomination Committee, +46-8-666-64-00    
Per Lorentz, Vice President Corporate Communications, +46-8-788-52-51, [email protected]
Johan Karlsson, Vice President Investor Relations, +46-8-788-51-30, [email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/essity/r/the-nomination-committee-proposes-unchanged-board-fees,c3078306

The following files are available for download:

https://mb.cision.com/Main/15798/3078306/1221984.pdf

 The Nomination Committee proposes unchanged Board fees

SOURCE Essity


These press releases may also interest you

at 06:15
The "Global Immune Health Supplements Market - Outlook & Forecast 2023-2028" report has been added to  ResearchAndMarkets.com's offering. The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach...

at 05:45
The Gross Law Firm issues the following notice to shareholders of Amplitude, Inc. . Shareholders who purchased shares of AMPL during...

at 05:45
The Gross Law Firm issues the following notice to shareholders of Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II ....

at 05:30
The "Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and by Country. With Market Analysis and Executive Guides. 2024 to 2028" report has been added to...

at 05:00
The "Immunoassay Markets. Strategies and Trends. Forecasts by Application, Technology, Product, User and by Country. With Executive Guides, Customized Forecasting and Analysis. 2023 to 2027" report has been added to ResearchAndMarkets.com's offering....

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...



News published on and distributed by: